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Abstract 
There is a need for researchers to have easy reference to the wide spectrum of different types of 
quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on 
QoL in AD do not cover the full spectrum of QoL measures used in studies on AD. This paper, 
on behalf of the European Academy of Dermatology and Venereology (EADV) Task Force on 
QoL contains information on instruments available for health-related QoL and family QoL 
assessment in AD including information on validation, experience of QoL assessment in AD for 
different purposes, peculiarities of QoL assessment in different age groups, expert analysis of 
available instruments including data on limitations of their use and recommendations of the Task 








There is a need for researchers to have easy reference to the wide spectrum of different types of 
quality of life (QoL) instruments that can be used in atopic dermatitis (AD). Previous reviews on 
QoL in AD do not cover the full spectrum of QoL measures used in studies on AD.1  A recent 
review on QoL instruments in adult AD2 did not identify a specific QoL instrument to be 
recommended for use in adult AD patients.  This paper, on behalf of the European Academy of 
Dermatology and Venereology (EADV) Task Force (TF) on QoL contains information on 
instruments available for health-related (HR) QoL and family QoL assessment in AD including 
information on validation, experience of QoL assessment in AD for different purposes, 
peculiarities of QoL assessment in different age groups, expert analysis of available instruments 
including data on limitations of their use and recommendations of the Task Force.  Although we 
do not attempt to define the “best” QoL instrument, the information provided should help 
dermatologists and researchers to choose appropriate QoL instruments and avoid common 
mistakes. 
Methods 
Members of the European Task Force on Atopic Dermatitis were invited to participate and Prof. 
Oranje agreed to join the working group. The literature search was performed using the PubMed 
database, which was searched from 1990 to November 2015 using the key word combinations: 
“Atopic dermatitis, quality of life” and “Atopic eczema, quality of life”.  All publications written 
in English or that had English abstracts were considered.  Duplicated and unrelated references 
and review articles were excluded. The remaining sources were analyzed and a list of QoL 
instruments that were used in AD was formed. Additional searches for “Name of measure” and 
“Atopic dermatitis/eczema” for each of the measures from this list was done. The results are 
presented in three sections: instruments for HRQoL and family QoL assessment in AD; 
peculiarities of QoL assessment in different age groups of patients with AD; reasons why QoL 
assessment may be useful in AD. 
Results 
HRQoL and family QoL instruments in AD 
A list of generic, dermatology-specific and AD-specific instruments with brief descriptions and 
information on validation are presented in Tables 1-3. In several publications42,43 the names of 
the QoL instruments used are not given.  In some other studies unvalidated “study-specific” 
instruments were used, some brief and simple44-47 and others more complicated.48-52 A 
“modified” DLQI was used in one study to measure the impairment of “itch-related” QoL.53 
Some QoL instruments with non-English original versions are given alternative titles in different 
publications. For example, Fragebogen Alltagsleben  (FAL), ALLTAG and “Daily life” are 
alternative titles of the same German instrument.16    
QoL assessment in different age groups of patients with AD 
We did not find information concerning specific aspects of HRQoL that may be affected 
differently in different age groups of adults with AD. There are several AD-specific HRQoL 
instruments created especially for children.  Most studies on QoL in young AD patients used the 
Infants Dermatitis Quality of Life Index (IDQoL)31. However, other AD-specific proxy-
instruments, the Childhood Atopic Dermatitis Impact Scale (CADIS) encompassing mixed proxy 
and family QoL37 and the Childhood Impact of Atopic Dermatitis (CIAD)40 were also used. The 
most widely used instrument for self-assessment of HRQoL in children with AD is the 
dermatology-specific Children’s Dermatology Life Quality Index (CDLQI).18 Several generic 
instruments have also been used to assess QoL of AD children: these include  Fragebogen für 
KINDer und Jugendlichezur Erfassung der gesundheitsbezogenen Lebensqualität  (KINDL)6, 
Quality of Life Scale for Children (AUQEI)7, DISABKIDS Chronic Generic Measure (DCGM-
37)10, Pediatric Quality of Life Inventory (PedsQL)15, Vécu et Santé Perçue de l'Adolescent 
(VSP-A) 14, Children's Quality of Life Index (CLQI)17, FAL/ALLTAG16 and AD-specific  
DISABKIDS AD Module (ADM)36. Because the lives of children alter greatly between the ages 
of 4 and 16 years, in the consideration of HRQoL children are not a homogenous group. Jirakova 
et al.54 divided children into two age groups, 7-13 years and 14-18 years, and found significant 
differences in two CDLQI items: problems in playing and doing hobbies and problems during 
school or holidays.  
Several AD-specific family QoL instruments have been created to try to measure the secondary 
impact of having someone in the family with AD on the QoL of other family members.  These 
include the Dermatitis Family Impact (DFI)34, Quality of life in Primary Caregivers of Children with 
AD (QPCAD)35, Parents' Index Quality of Life-AD (PIQoL-AD)38, The Quality of Life in Parents 
of Children with AD39 and CADIS (mixed proxy and family QoL instrument).37 The 
dermatology-specific Family Dermatology Life Quality Index (FDLQI) was created to measure 
the impact in family members of patients with all skin diseases and from all age groups.19 The 
FDLQI may be as effectively used by parents of children with AD as it can be used by family 
members of adult dermatology patients.55  
 
Use of Qol Measures in unvalidated or inappropriate age groups 
An important issue is the quite frequently reported use of HRQoL instruments out of their 
validated age limits. For example Skindex-29, an instrument for adults, was used in children 
from 13 years old56 and the DLQI, designed for use in those over 16 years old, was used in 
children from 8 years old.57 The CDLQI, originally validated for use in children from 4 to 16 
years old, was used in children aged 3 years58, 2 years59-62 and even 1 year of age.63,64 The 
IDQoL has been used in children under 654 and 7 years of age65, though it is only meant to be 
used in infants. Using this measure in older children was explained as being necessary because 
of the education system in the Czech Republic.54 The IDQOL is recommended to be used by 
children aged from newborn to 3 years of age and CDLQI by children from 4 to 16 years of age.  
The lower age cutoff was chosen because of the way in which a four year old behaves and the 
relevance of the questions to this age group.  Although reasons were given54 why in a study in 
the Czech Republic different age limits were applied for the use of the IDQoL and CDLQI, the 
original validated age recommendations remain those recommended by the authors. The scores 
of 33 teenagers with AD were presented as part of the data used for validation of the 
dermatology-specific Skindex-teen questionnaire.66 The generic HRQoL instrument for 
adolescents, VSP-A, was used in French children during the validation of the DISABKIDS 
instrument.10 The dermatology-specific CDLQI questionnaire67 has been used to study the 
specific problems experienced by adolescents. 
Reasons for assessment of QoL in AD  
Clinical trials 
Several different QoL instruments have been used in clinical trials of AD as outcome measures 
(Table 4). The DLQI and CDLQI have been the most frequently used, and the IDQoL and DFI 
are the most widely used AD-specific and infant and family QoL instruments. In some clinical 
trials “study-specific” non-validated instruments were used.45,49,47,119   Reports of other trials do 
not contain information on which HRQoL instruments were used.42,120 
Impairment of HRQoL and family QoL  
Several questionnaires were used simultaneously in studies of how QoL is impacted in AD 
patients and their families (Table 4).  
Creation and validation of instruments  
Several publications describe the creation and validation of QoL instruments, and their culturally 
validated local versions, in AD patients and in parents/caregivers (Table 4). The DLQI, DFI and 
PIQoL-AD have also been used in the validation process of non-QoL instruments.121-123  
Correlation of QoL and AD severity 
Many authors have presented data on the correlation of QoL and AD severity as a secondary 
outcome, but in addition there are several studies primarily aiming to study this correlation. 
Correlations have been reported between the generic measure Short Form Health Survey (SF-
36), dermatology-specific measures DLQI, CDLQI, Skindex-29, AD-specific measures IDQoL, 
the family QoL measure DFI, the German questionnaire “Quality of life in parents of children 
with atopic dermatitis”, and PIQoL-AD, along with scoring of AD (SCORAD), patient oriented 
(PO)-SCORAD, Eczema Area and Severity Index (EASI) and other AD severity scales.123-131 
There have been significant positive correlations between DLQI, IDQOL, DFI with SCORAD125-
126
, and some studies not finding such correlation.128,132 DLQI, DFI, IDQoL and CDLQI were 
well correlated with PO-SCORAD, suggesting the importance of the patient’s perspective.129-130 
Self-assessed HRQoL of children with AD correlated better with disease severity than family 
QoL results133. HRQoL measured by the DLQI, Skindex-29 and PIQoL-AD did not correlate 
with the severity of AD measured by the EASI.123-124  
Educational programs 
The QoL instruments that have been used to assess the efficacy of different educational 
programs are given in Table 4. The impact of support groups on HRQoL has been measured 
using the CDLQI, improving personal relationships and leisure time.103 DFI scores suggested 
that involvement with support groups103 or undertaking a two day parental education 
programme134 is not enough to improve family QoL.   However the importance of intensive 
educational programmes in children (5-16 years old) was confirmed by an improvement of the 
IDQOL, CDLQI and DFI scores.135  Web-based education programs had a beneficial effect on 
the HRQoL of AD children, as measured by the IDQoL.136 Parental counseling sessions about 
medical, nutritional and psychological issues improved treatment habits, costs and coping 
strategies in a study using the FAL/ALLTAG questionnaire.107  Another German questionnaire 
“QoL in parents of children with atopic dermatitis” was used to analyze the impact of longer 
educational programmes for parents of AD children and teenagers. There were better results in 
children less than 7 years old.137 The same measure was used to show that child-parent 
interventions could change the psychological parameters that could influence adherence and the 
success of therapy, by improving their coping strategies for control of scratching.105 Six weekly 
meetings as part of a multidisciplinary approach involving a pediatric allergist, dermatologist and 
psychologist had a significant improvement on IDQOL and DFI scores, also decreasing the 
levels of parents’ anxiety.104  DLQI and CDLQI scores have revealed the impact of daily text 
messages for six weeks as medication reminders and education for teens and adults.138 The on-
line self-management programme “Living with eczema” improves DLQI scores.139 DLQI and 
SCORAD scores were significantly improved by referral of atopic adults to secondary care, 
probably due to decreasing worries and concerns regarding their disease.140 
Impact of AD and other diseases 
Generic and dermatology-specific HRQoL instruments that have been used to compare the 
impact of AD and other diseases are given in Table 4. These studies confirmed that AD has a 
high impact on social functioning and psychological well-being, similar to other chronic 
dermatological conditions (psoriasis, Darier’s disease and Hailey-Hailey disease), hypertension, 
depression and type II diabetes.141 The use of the DLQI, Skindex-29 and the EQ-5D in large 
population studies showed lower QoL in people with self-reported skin diseases (including AD) 
than in the general population.108 Chronic diseases such as AD had a higher impact on QoL, as 
measured by the CDLQI and AUQEI, than molluscum contagiosum.117 In children, AD and 
psoriasis result in the highest CDLQI scores, followed by urticaria and acne.17 Vitiligo may 
cause greater impairment of HRQoL, assessed by the CDLQI, than AD.109 Generalized AD 
resulted in greater impairment of QoL than severe systemic diseases such as cystic fibrosis, 
asthma, epilepsy or diabetes.17 Skindex-29 scored more highly in AD than in “intrinsic AD”.56 
Use of the KINDL-R showed that acute AD and hay fever could have a higher impact on QoL 
than asthma.113 Young, single, poor patients with a long-duration of AD, psoriasis, vitiligo and 
acne report a lower QoL.142 Use of the generic measure, SF-12, has shown that psoriasis patients 
may experience a greater impact on their QoL and higher perceived stress than AD patients.112 
Using the DLQI and Skindex-16 it was shown that psoriasis has a higher effect on desire to be 
with people, showing affection and causing more problems with the treatment, whereas in AD 
itching causes higher negative impact on QoL. Psoriatic patients with only mild disease may 
experience a large negative effect on their QoL, a scenario not typical for AD patients.110 A 
study using the Adjustment to Chronic Skin Diseases Questionnaire (ACSD) suggested that the 
impact of psoriasis is greater than that of AD.118 Another study showed that only arthropathic 
psoriasis had a higher impact on HRQoL than AD, as measured by the SF-36 and the DLQI.143 
DLQI measurement showed that in both psoriasis and AD, hospitalization could have a positive 
effect on QoL.144 The willingness to pay in both AD and psoriasis correlates with DLQI 
scores.145 DLQI scores are better correlated with measures of depression, anxiety and personal 
interactions in AD than in vitiligo or healthy controls.146  
Other reasons to assess QoL in AD 
Other studies where QoL of AD patients and/or their families was studied are given in Table 5.  
Discussion 
The use of a wide range of QoL instruments has confirmed the impairment of QoL experienced 
by AD patients and their family members. Despite there being a range of reported correlations 
between HRQoL instruments and AD severity measures128,129, it is clear that HRQoL is generally 
more impaired in patients who have a more severe clinical course of AD.  
Generic instruments should be used to compare QoL impairment in AD with non-dermatologic 
conditions: dermatology-specific instruments may be used to compare QoL across different skin 
diseases. However, Twiss and McKenna176 used two disease-specific instruments that were 
created on the same principles (PSORIQoL and QoLIAD) to compare QoL impairment in AD 
and psoriasis. Dermatology-specific and disease-specific questionnaires may have a greater 
capacity for differentiation and be more sensitive to change than generic measures. Using a 
questionnaire which is not specifically tailored to the disease could mean that some issues 
associated with the disease are not recorded.177  When the  generic SF-36 was used in AD, there 
were only small score differences between patients with mild and moderate eczema and between 
mild eczema and healthy controls, and no significant correlation with AD severity, in contrast 
with reported correlations using the dermatology-specific DLQI and CDLQI.178  
There are many types of validated HRQoL instruments. Questionnaires should be tested for scale 
structure, reliability, validity and responsiveness. Additional validation methods are used to 
assess the quality of instruments. However some researchers have used “study-specific” 
instruments without any validation. Such practice negates the scientific value of the published 
results and may discredit HRQoL assessment. It is impossible to rely on the results of studies 
when authors do not mention the name of the QoL instrument used: authors should always give 
the names of any QoL instruments used in reported studies.  Where a single instrument has more 
than one descriptive title, the original title should be given, along with the original reference to 
its publication, in order to avoid confusion. Editors should ensure that published QoL data at 
least meets these minimum requirements. The use of modified versions of validated instruments 
is often described. However, such adapted questionnaires should be fully revalidated.  
As the QoL impacts experienced by people aged 16-17 may differ from those experienced 
by children or adults, QoL measures designed for use in this age range may have advantages over 
both child- and adult-specific measures.179 Though AD is relatively uncommon in the elderly, the 
numbers of elderly patients with AD are gradually increasing in industrialized countries, 
associated with an aging society.180  There may be specific ways in which elderly people are 
affected by AD that result in specific needs: prospective research is required to address this. 
It is possible to capture, with parental assistance, self assessment of QoL in children as young as 
four years old, with the help of illustrated questionnaires. In younger children outsider or proxy 
ratings can be used, but this brings with it the potential problem of adult-child concordance.181,182  
Because of possible discrepancy between self and proxy reports we recommend that proxy-rating 
questionnaires should only be used as a single measure in the youngest age group and in those 
patients who are unable to self-assess.  Spouses can report differing views, not associated with 
gender.183 Therefore it would seem better to involve both parents in completing proxy rated 
questionnaires, though this may be impractical. Cartoon versions of the questionnaires are 
preferable, especially for the youngest patients. 
Questionnaires should be selected that are appropriate for the ages of the subjects studied. If 
instruments have to be used out of their validated age limits, they should be revalidated.  
Some reports have combined scores of the DLQI and CDLQI: such combination is 
inappropriate184 as these instruments have different questions specific to the age groups for 
which the questionnaires are designed. The validated score banding descriptors, for example, are 
different. 
The selection of an appropriate HRQoL instrument in clinical research or practice depends on 
the research question and the target population in which the HRQoL instrument is 
administered.185  We recommend the use of validated AD-specific instruments in addition to 
generic and dermatology-specific questionnaires. The use of novel instruments with limited 
validation and lack of validated translations may meet the needs of a local study, but such use 
will inevitably limit comparability and interpretation of the results in a wider context.  Because 
of the significant family impact of AD we recommend that family QoL should be further studied, 
especially concerning young children. This may help to improve clinical consultations and 
choice of appropriate treatment strategy.  
This publication has focused on the large numbers of published research studies using QoL 
measures in AD.  However there is virtually no information about the routine use of QoL 
measures in the routine management of such patients, a question that is arguably of greater 
practical importance to clinicians.  If physicians choose to use a QoL measure in clinical 
practice, then issues such as simplicity of use and ability to interpret scores become of great 
importance. 
Limitations 
Because of space limitations and the high number of articles on QoL in AD, the number of 
references identified and reported per instrument in this paper may not reflect the actual 
frequency of the use of that instrument.  
Conclusion 
The summarized recommendations of the Task Force are presented in Table 6 and Figures 1 and 
2. This paper should help dermatologists and researchers to choose appropriate QoL instruments 
for their needs and avoid common mistakes. 
References 
1. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic 
review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS 
One 2011;13:e17520. 
2. Heinl D, Prinsen CA, Deckert S et al. Measurement properties of adult quality-of-life 
measurement instruments for eczema: a systematic review. Allergy 2016;71:358-70. 
3. Janssen MF, Pickard AS, Golicki D et al. Measurement properties of the EQ-5D-5L 
compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life 
Res 2013;22:1717–27. 
4. Brazier JE, Harper R, Jones NM et al. Validating the SF-36 health survey questionnaire: 
new outcome measure for primary care. BMJ 1992;305:160–4. 
5. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of 
scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220–33. 
6. Erhart M, Ellert U, Kurth B, Ravens-Siebere U. Measuring adolescents' HRQoL via self 
reports and parent proxy reports: an evaluation of the psychometric properties of both 
versions of the KINDL-R instrument. Health Qual Life Outcomes 2009;7:77. 
7. Assumpção FB, Kuczynski E, Sprovieri MH, Aranha EM. Escala de avaliação de 
qualidade de vida. Arq Neuropsiquiatr 2000;58:119–27. 
8. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®): 
concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:1. 
9. Raat H, Botterweck A, Landgraf J, Hoogeveen W, Essink-Bot M. Reliability and validity 
of the short form of the child health questionnaire for parents (CHQ-PF28) in large 
random school based and general population samples. J Epidemiol  Community Health 
2005;59:75-82. 
10. Simeoni M-C, Schmidt S, Muehlan H, Debensason D, Bullinger M, DISABKIDS Group. 
Field testing of a European quality of life instrument for children and adolescents with 
chronic conditions: the 37-item DISABKIDS Chronic Generic Module. Qual Life Res 
2007;16:881–93. 
11. Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-
BREF quality of life assessment: psychometric properties and results of the international 
field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299–310. 
12. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of sickness impact profile 
and psoriasis disability index in psoriasis. Br J Dermatol 1990;123:751–6. 
13. Sánchez R, Ballesteros M, Arnold BJ. Validation of the FACT-G scale for evaluating 
quality of life in cancer patients in Colombia. Qual Life Res 2011;20:19–29. 
14. Sapin C, Simeoni M-C, Khammar M El, Antoniotti S, Auquier P. Reliability and validity 
of the VSP-A, a health-related quality of life instrument for ill and healthy adolescents. J 
Adolesc Health 2005;36:327–36. 
15. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric 
Quality of Life Inventory version 4.0. generic core scales in healthy and patient 
populations. Med Care 2001;39: 800–12. 
16. Bullinger M, Kirchberger I, Von Steinbuchel N. The questionnaire ‘Daily life’ – an 
instrument for assessing health related quality of life. Z Med Psychol 1993:3:121–31. 
17. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in 
children with skin disease and children with other chronic childhood diseases. Br J 
Dermatol 2006;155:145–51. 
18. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): 
Initial validation and practical use. Br J Dermatol 1995;132:942-9. 
19. Basra MKA, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index; 
measuring the secondary impact of skin disease. Br J Dermatol 2007;156:528–38. 
20. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative 
capability of a refined version of Skindex, a quality-of-life instrument for patients with 
skin diseases. Arch Dermatol 1997;133:1433-40. 
21. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16, A 
brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 
2001;5:105–10.  
22. Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using 
Rasch analysis: Skindex-17. J Invest Dermatol 2006;126:1244-50. 
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical 
measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6. 
24. Evers AW, Duller P, van de Kerkhof PC. The Impact of Chronic Skin Disease on Daily 
Life (ISDL): a generic and dermatology-specific health instrument. Br J 
Dermatol 2008;158:101-8. 
25. Augustin M, Zschocke I, Seidenglanz K, Lange S, Schiffler A, Amon U. Validation and 
Clinical Results of the FLQA-d, a Quality of Life Questionnaire for Patients with 
Chronic Skin Disease. Dermatol Psychosom 2000;1:12-17. 
26. Schäfer T, Staudt A, Ring J. German instrument for the assessment of quality of life in 
skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant 
validity and responsiveness. Hautarzt 2001;52:624-8.       
27. Grob JJ, Auquier P, Martin S, Lançon C, Bonerandi JJ. Development and validation of a 
quality of life measurement for chronic skin disorders in french: VQ-Dermato. The 
Réseaud Epidémiologie en Dermatologie. Dermatology 1999;199:213-22. 
28. Stangier U, Ehlers A, Gieler U. Measuring Adjustment to Chronic Skin Disorders: 
Validation of a Self-Report Measure. Psychol Assess 2003;15:532-49.          
29. Augustin M, Zschocke I, Wiek K et al. Krankheitsbewaltigung und Lebensqualitat bei 
Patienten mit Feuermalen unter Lasertherapie. Hautarzt 1998;49:714–8. 
30. Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-
related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad 
Dermatol 2001;44:S65–72.             
31. Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants' Dermatitis Quality of Life Index. Br 
J Dermatol 2001;144:104-10. 
32. Taïeb A, Boralevi F, Seneschal J et al. Atopic Dermatitis Burden Scale for Adults: 
Development and Validation of a New Assessment Tool. Acta Derm Venereol 
2015;95(6):700-5. 
33. Whalley D, McKenna SP, Dewar AL et al. A new instrument for assessing quality of life 
in atopic dermatitis: international development of the Quality of Life Index for Atopic 
Dermatitis (QoLIAD). Br J Dermatol 2004;150(2):274-83.  
34. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG. The family impact of 
childhood atopic dermatitis: the Dermatitis Family Impact questionnaire. Br J Dermatol 
1998;138:107–13. 
35. Kondo-Endo K, Ohashi Y, Nakagawa H et al. Development and validation of a 
questionnaire measuring quality of life in primary caregivers of children with atopic 
dermatitis (QPCAD). Development and validation of a questionnaire measuring quality 
of life in primary caregivers of children with atopic dermatitis (QPCAD). Br J Dermatol 
2009;161:617-25. 
36. Baars R, Atherton C, Koopman H, Billinger M, Power M and the DISABKIDS group. 
The European DISABKIDS project: development of seven condition-specific modules to 
measure health related quality of life in children and adolescents. Health Qual Life 
Outcomes 2005;3:70. 
37.
 Chamlin SL, Cella D, Frieden IJ et al. Development of the Childhood Atopic Dermatitis 
Impact Scale: initial validation of a quality-of-life measure for young children with atopic 
dermatitis and their families. J Invest Dermatol 2005;125:1106-11.  
38. McKenna SP, Whalley D, Dewar AL, Erdman RA, Kohlmann T, Niero M, Baró E, Cook 
SA, Crickx B, Frech F, van Assche D. International development of the Parents' Index of 
Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res. 2005;14(1):231-41. 
39. Von Ruden U, Kehrt R, Staab D, Wahn U. Development and validation of a disease 
specific questionnaire on quality of life of parents of children with atopic dermatitis. ZF 
Gesundheitswiss 1999;4:335–50. 
40. McKenna SP, Doward LC, Meads DM, Tennant A, Lawton G, Grueger J. Quality of life 
in infants and children with atopic dermatitis: addressing issues of differential item 
functioning across countries in multinational clinical trials. Health Qual Life Outcomes 
2007;5:45. 
41. Salek MS, Finlay AY, Luscombe DK et al. Cyclosporin greatly improves the quality of 
life of adults with severe atopic dermatitis. A randomized, double- blind, placebo-
controlled trial. Br J Dermatol 1993;129:422-30. 
42. Baltás E, Csoma Z, Bodai L, Ignácz F, Dobozy A, Kemény L. Treatment of atopic 
dermatitis with the xenon chloride excimer laser. J Eur Acad Dermatol Venereol 
2006;20:657-60.  
43. Roll S, Reinhold T, Pach D et al. Comparative effectiveness of homoeopathic vs. 
conventional therapy in usual care of atopic eczema in children: long-term medical and 
economic outcomes. PLoS One 2013;8:e54973. 
44. Betlloch I, Izu R, Lleonart M, Ferrer M, Ferrando J. Investigadores del estudio ACTIDA. 
Attitude of the adult patient with atopic dermatitis to the disease and its treatment: the 
ACTIDA Study. Acta Dermosifiliogr 2010;101:143-50. 
45. Hjelmgren J, Svensson A, Jörgensen ET, Lindemalm-Lundstam B, Ragnarson Tennvall 
G. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with 
moderate and severe atopic dermatitis: a health-economic model simulation based on a 
patient survey and clinical trial data. Br J Dermatol 2007;156:913-21. 
46. Healy E, Bentley A, Fidler C, Chambers C. Cost-effectiveness of tacrolimus ointment in 
adults and children with moderate and severe atopic dermatitis: twice-weekly 
maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from 
a third party payer (U.K. National Health Service) perspective. Br J Dermatol 
2011;164:387-95. 
47. Kircik LH, Del Rosso JQ, Aversa D. Evaluating clinical use of a ceramide-dominant, 
physiologic lipid-based topical emulsion for atopic dermatitis. J Clin Aesthet Dermatol 
2011;4:34-40. 
48. Ito K, Imafuku S, Nakayama J. Therapeutic preferences are different in psoriatic and 
atopic dermatitis patients: a questionnaire-based study. J Dermatol 2013;40:292-4. 
49. Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior 
to fructo-oligosaccharide alone for treating children with moderate to severe atopic 
dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J 
Dermatol 2012;166:129-36.  
50. Berth-Jones J, Finlay AY, Zaki I et al. Cyclosporine in severe childhood atopic 
dermatitis: a multicenter study. J Am Acad Dermatol 1996;34:1016-21.  
51. Bissonnette R, Maari C, Provost N et al. A double-blind study of tolerance and efficacy 
of a new urea-containing moisturizer in patients with atopic dermatitis. J Cosmet 
Dermatol 2010;9:16-21. 
52. Chou JS, LeBovidge J, Timmons K, Elverson W, Morrill J, Schneider LC. Predictors of 
clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy 
Asthma Proc 2011;32:377-83. 
53. Zachariae R, Lei U, Haedersdal M, Zachariae C. Itch severity and quality of life in 
patients with pruritus: preliminary validity of a Danish adaptation of the itch severity 
scale. Acta Derm Venereol 2012;92:508-14. 
54. Jiráková A, Vojáčková N, Göpfertová D, Hercogová J. A comparative study of the 
impairment of quality of life in Czech children with atopic dermatitis of different age 
groups and their families. Int J Dermatol 2012;51:688-92. 
55. Chernyshov PV, Kaliuzhna LD, Reznikova AA, Basra MK. Comparison of the 
impairment of family quality of life assessed by disease-specific and dermatology-
specific instruments in children with atopic dermatitis. J Eur Acad Dermatol Venereol 
2015;29:1221-4. 
56. Brenninkmeijer EE, Spuls PI, Legierse CM, Lindeboom R, Smitt JH, Bos JD. Clinical 
differences between atopic and atopiform dermatitis J Am Acad Dermatol 2008;58:407-
14.  
57. Kircik L. The effect of desonide hydrogel on pruritis associated with atopic dermatitis. J 
Drugs Dermatol 2014;13:725-8. 
58. Darné S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with 
moderate-to-severe eczema: a comparative cohort study.Br J Dermatol 2014;170:150-6. 
59. Kondo Y, Nakajima Y, Komatsubara R et al. Short-term efficacy of tacrolimus ointment 
and impact on quality of life. Pediatr Int 2009;51:385-9. 
60. Sánchez-Pérez J, Daudén-Tello E, Mora AM, Lara Surinyac N. Impact of atopic 
dermatitis on health-related quality of life in Spanish children and adults: the PSEDA 
study. Actas Dermosifiliogr 2013;104:44-52. 
61. Onumah N, Kircik L. Pimecrolimus cream and Tacrolimus ointment in the treatment of 
atopic dermatitis: a pilot study on patient preference. J Drugs Dermatol 2013;12:1145-8.  
62. Singalavanija S, Noppakun N, Limpongsanuruk W et al. Efficacy and safety of 
tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.  J 
Med Assoc Thai 2006;89(11):1915-22.  
63. Farina S, Gisondi P, Zanoni M et al. Balneotherapy for atopic dermatitis in children at 
Comano spa in Trentino, Italy. J Dermatolog Treat 2011;22:366-71.  
64. Hon KL, Wong KY, Cheung LK et al. Efficacy and problems associated with using a 
wet-wrap garment for children with severe atopic dermatitis. J Dermatolog Treat 
2007;18:301-5.  
65. Ricci G, Bendandi B, Bellini F, Patrizi A, Masi M. Atopic dermatitis: quality of life of 
young Italian children and their families and correlation with severity score. Pediatr 
Allergy Immunol 2007;18:245-9. 
66. Smidt AC, Lai JS, Cella D, Patel S, Mancini AJ, Chamlin SL. Development and 
Validation of Skindex-Teen, a Quality-of-Life Instrument for Adolescents With Skin 
Disease. Arch Dermatol 2010;146:865-9. 
67. Slattery MJ, Essex MJ, Paletz EM et al. Depression, anxiety, and dermatologic quality of 
life in adolescents with atopic dermatitis. J Allergy Clin Immunol 2011;128:668-71. 
68. Lyakhovitsky A, Barzilai A, Heyman R et al. Low-dose methotrexate treatment for 
moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 
2010;24:43-9. 
69. McKenna SP, Whalley D, de Prost Y. Treatment of paediatric atopic dermatitis with 
pimecrolimus (Elidel, SDZ ASM 981): impact onquality of life and health-related quality 
of life. J Eur Acad Dermatol Venereol 2006;20:248-54. 
70. Janmohamed SR, Oranje AP, Devillers AC et al. The proactive wet-wrap method with 
diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, 
randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014;70:1076-
82. 
71. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New 
emollient with topical corticosteroid-sparing effect in treatment of childhood atopic 
dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol 2008;25:606-
12. 
72. Wang IJ, Wang JY. Children with atopic dermatitis show clinical improvement after 
Lactobacillus exposure. Clin Exp Allergy 2015;45:779-87. 
73. Åkerström U, Reitamo S, Langeland T et al. Comparison of Moisturizing Creams for the 
Prevention of Atopic Dermatitis Relapse: A Randomized Double-blind Controlled 
Multicentre Clinical Trial. Acta Derm Venereol 2015;95:587-92. 
74. Gambichler T, Othlinghaus N, Tomi NS et al. Medium-dose ultraviolet (UV) A1 vs. 
narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J 
Dermatol 2009;160:652-8. 
75. Patel AN, Langan SM, Batchelor JM. A randomized trial of methotrexate vs. 
azathioprine for severe atopic eczema: a critical appraisal. Br J Dermatol 2012;166:701-
4; discussion 704. 
76. Kawakami T, Kimura S, Haga T et al. Health-related quality of life assessed by the effect 
of bepotastine besilate in patients with pruritus: importance of emotions score in atopic 
dermatitis. J Dermatol 2012;39:527-30. 
77. Bostoen J, Bracke S, De Keyser S, Lambert J. An educational programme for patients 
with psoriasis and atopic dermatitis: a prospective randomized controlled trial. Br J 
Dermatol 2012;167:1025-31. 
78. Poole CD, Chambers C, Allsopp R, Currie CJ. Quality of life and health-related utility 
analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus 
ointment vs. topical corticosteroids. J Eur Acad Dermatol Venereol 2010;24:674-8. 
79. Taieb C, Sibaud V, Merial-Kieny C. Impact of Avène hydrotherapy on the quality of life 
of atopic and psoriatic patients. J Eur Acad Dermatol Venereol 2011;25 Suppl 1:24-9. 
80. Torrelo A, Ortiz J, Alomar A, Ros S, Pedrosa E, Cuervo J. Health-related quality of life, 
patient satisfaction, and adherence to treatment in patients with moderate or severe atopic 
dermatitis on maintenance therapy: the CONDA-SAT study. Actas Dermosifiliogr 
2013;104:409-17. 
81. Wolf P, Georgas D, Tomi NS, Schempp CM, Hoffmann K. Extracorporeal 
photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: 
results from a prospective trial. Photochem Photobiol Sci 2013;12:174-81. 
82. Kim NK, Lee DH, Seo HS et al. Hwangryunhaedoktang in adult patients with atopic 
dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial--study 
protocol. BMC Complement Altern Med 2011;11:68. 
83. Heinlin J, Schiffner-Rohe J, Schiffner R et al. A first prospective randomized controlled 
trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB 
monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol 2011;25:765-73. 
84. Eberlein B, Gulyas A, Schultz K. Benefits of alpine mountain climate of Bavaria in 
patients with allergic diseases and chronic obstructive pulmonary disease: results from 
the AURA study. J Investig Allergol Clin Immunol 2009;19:159-61. 
85. Witt CM, Brinkhaus B, Pach D et al.Homoeopathic versus conventional therapy 
for atopic eczema in children: medical and economic results. Dermatology 2009;219:329-
40. 
86. De Backer M, Morren MA, Boonen H et al. Belgian observational drug utilization study 
of pimecrolimus cream 1% in routine daily practice inatopic dermatitis. Dermatology 
2008;217:156-63. 
87. Kawashima M; QOL Research Forum for Patients with Atopic Dermatitis. Quality of life 
in patients with atopic dermatitis: impact of tacrolimus ointment. Int J Dermatol 
2006;45:731-6. 
88. Granlund H, Erkko P, Remitz A et al. Comparison of cyclosporin and UVAB 
phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm 
Venereol 2001;81:22-7. 
89. Misery L, Finlay AY, Martin N et al. Atopic dermatitis: impact on the quality of life of 
patients and their partners. Dermatology 2007;215:123-9. 
90. Ražnatović Djurović M, Janković J, Tomić Spirić V, Janković S. Health-related Quality 
of Life in Children with Moderate to Severe Atopic Dermatitis. Acta Dermatovenerol 
Croat 2015;23:178-84. 
91. Ricci G, Bendandi B, Pagliara L, Patrizi A, Masi M. Atopic dermatitis in Italian children: 
evaluation of its economic impact. J Pediatr Health Care 2006;20:311-5.  
92. Chernyshov PV, Jirakova A, Ho RС et al. An international multicenter study on quality 
of life and family quality of life in children with atopic dermatitis. Indian J Dermatol 
Venereol Leprol 2013;79:52-8. 
93. Pustišek N, Vurnek Živković M, Šitum M. Quality of Life in Families with Children with 
Atopic Dermatitis. Pediatr Dermatol 2016;33:28-32.  
94. Higaki Y, Kawamoto K, Kamo T, Ueda S, Arikawa J, Kawashima M. Measurement of 
the impact of atopic dermatitis on patients' quality of life: a cross-sectional and 
longitudinal questionnaire study using the Japanese version of Skindex-16. J Dermatol 
2004;31:977-82. 
95. Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health-
related quality of life in patients with atopic dermatitis. J Dermatol 2012;39:42-7.  
96. Tan Q, Yang H, Wang H. Quality of life in children with atopic dermatitis. Zhongguo 
Dang Dai Er Ke Za Zhi 2010;12:351-3. 
97. Meads DM, McKenna SP, Kahler K. The quality of life of parents of children with atopic 
dermatitis: interpretation of PIQoL-AD scores. Qual Life Res 2005;14:2235-45. 
98. Chernyshov PV. Creation and cross-cultural adaptation of Ukrainian versions of 
questionnaires for assessment of quality of life of children with atopic dermatitis and 
their families. Lik Sprava 2008;1-2:124-8. 
99. Augustin M, Wenninger K, Amon U. German adaptation of the Skindex-29 questionnaire 
on quality of life in dermatology: validation and clinical results. Dermatology 
2004;209:14-20. 
100. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I. 
Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core 
questionnaire and development of a threshold system. Eur J Dermatol 2004;14:107-13. 
101. Warschburger P, Landgraf JM, Petermann F, Freidel K. Health-related quality of 
life in children assessed by their parents: evaluation of the psychometric properties of the 
CHQ-PF50 in two German clinical samples. Qual Life Res 2003;12:291-301. 
102. Deon KC, Santos DM, Bullinger M, Santos CB. Preliminary psycometric 
assessment of the Brazilian version of the DISABKIDS Atopic Dermatitis Module. Rev 
Saude Publica 2011;45:1072-8.               
103. Weber MB, Fontes Neto Pde T, Prati C. Improvement of pruritus and quality of 
life of children with atopic dermatitis and their families after joining support groups. J 
Eur Acad Dermatol Venereol 2008;22:992-7.     
104. Ricci G, Bendandi B, Aiazzi R, Patrizi A, Masi M. Three years of Italian 
experience of an educational program for parents of young children affected by atopic 
dermatitis: improving knowledge produces lower anxiety levels in parents of children 
with atopic dermatitis. Pediatr Dermatol 2009;26:1-5. 
105.  Breuer K, Matterne U, Diepgen TL et al. Predictors of benefit from an atopic 
dermatitis education programme. Pediatr Allergy Immunol 2014;25:489-95. 
106. van Os-Medendorp H, Koffijberg H, Eland-de Kok PC et al. E-health in caring for 
patients with atopic dermatitis: a randomized controlled cost-effectiveness study of 
internet-guided monitoring and online self-management training. Br J Dermatol 
2012;166:1060-8. 
107. Staab D, von Rueden U, Kehrt R et al. Evaluation of a parental training program 
for the management of childhood atopic dermatitis. Pediatr Allergy Immunol 2002;13:84-
90. 
108. Vinding GR, Knudsen KM, Ellervik C, Olesen AB, Jemec GB. Self-reported skin 
morbidities and health-related quality of life: a population-based nested case-control 
study. Dermatology 2014;228:261-8. 
109. Dertlioğlu SB, Cicek D, Balci DD, Halisdemir N. Dermatology life quality index 
scores in children with vitiligo: comparison with atopic dermatitis and healthy control 
subjects. Int J Dermatol 2013;52:96-101. 
110. Chernyshov PV. Health related quality of life in adult atopic dermatitis and 
psoriatic patients matched by disease severity. G Ital Dermatol Venereol 2016;151:37-43. 
111. Chen YC, Wu CS, Lu YW et al. Atopic dermatitis and non-atopic hand eczema 
have similar negative impacts on quality of life: implications for clinical significance. 
Acta Derm Venereol 2013;93:749-50. 
112. Misery L, Thomas L, Jullien D et al. Comparative study of stress and quality of 
life in outpatients consulting for different dermatoses in 5 academic departments of 
dermatology. Eur J Dermatol 2008;18:412-5. 
113. Matterne U, Schmitt J, Diepgen TL, Apfelbacher C. Children and adolescents' 
health-related quality of life in relation to eczema, asthma and hay fever: results from a 
population-based cross-sectional study. Qual Life Res 2011;20:1295-305. 
114. Petersen C, Schmidt S, Power M, Bullinger M; DISABKIDS Group. 
Development and pilot-testing of a health-related quality of life chronic generic module 
for children and adolescents with chronic health conditions: a European perspective. 
Qual Life Res 2005;14:1065-77. 
115. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin 
diseases: methodological and practical comparison of different quality of life 
questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999;50:715-22. 
116. Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the 
impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J 
Dermatol 2005;152:289-95. 
117. Weber MB, Lorenzini D, Reinehr CP, Lovato B. Assessment of the quality of life 
of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras 
Dermatol 2012;87:697-702. 
118. Leibovici V, Canetti L, Yahalomi S et al. Well being, psychopathology and 
coping strategies in psoriasis compared with atopic dermatitis: a controlled study. J Eur 
Acad Dermatol Venereol 2010;24:897-903. 
119. Kurtz EJ, Yelverton CB, Camacho FT, Fleischer AB Jr. Use of a silklike bedding 
fabric in patients with atopic dermatitis. Pediatr Dermatol 2008;25:439-43. 
120. Gollnick H, Luger T, Freytag S, Bräutigam M; STABIEL study group. StabiEL: 
stabilization of skin condition with Elidel-a patients' satisfaction observational study 
addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with 
topical corticosteroid. J Eur Acad Dermatol Venereol 2008;22:1319-25. 
121. Boleira M, Lupi O, Pires GV, Dias G, Seba AJ, Guimarães DB. Translation and 
validation of Portuguese of a questionnaire for evaluation of psychosomatic symptoms in 
adults with atopic dermatitis. An Bras Dermatol 2014;89:763-9.  
122. Wootton CI, Koller K, Lawton S, O'Leary C, Thomas KS; SWET study team. Are 
accelerometers a useful tool for measuring disease activity in children with eczema? 
Validity, responsiveness to change, and acceptability of use in a clinical trial setting. Br J 
Dermatol 2012;167:1131-7. 
123. Barbier N, Paul C, Luger T et al. Validation of the Eczema Area and Severity 
Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% 
randomized controlled clinical trials programme. Br J Dermatol 2004;150:96-102. 
124. Zhao CY, Tran AQ, Lazo-Dizon JP et al. A pilot comparison study of four 
clinician-rated atopic dermatitis severity scales. Br J Dermatol 2015;173:488-97.  
125. Kim DH, Li K, Seo SJ et al. Quality of life and disease severity are correlated in 
patients withatopic dermatitis. J Korean Med Sci 2012;27:1327-32.  
126. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are 
correlated in children with atopic dermatitis. Br J Dermatol 2004;150:284-90. 
127. Ben-Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity 
related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol 2002;16:455-62. 
128. Hon KL, Kam WY, Lam MC, Leung TF, Ng PC. CDLQI, SCORAD and NESS: 
are they correlated? Qual Life Res 2006;15:1551-8.  
129. Coutanceau C, Stalder JF. Analysis of correlations between patient-oriented 
SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and 
quality of life. Dermatology 2014;229:248-55.  
130. Boccardi D, D'Auria E, Turati F et al. Disease severity and quality of life in 
children with atopic dermatitis. The role of PO-SCORAD in clinical practice. Minerva 
Pediatr 2015 Jul 22. [Epub ahead of print] 
131. van Valburg RW, Willemsen MG, Dirven-Meijer PC, Oranje AP, van der 
Wouden JC, Moed H. Quality of life measurement and its relationship to disease severity 
in children with atopic dermatitis in general practice. Acta Derm Venereol 2011;91:147-
51.  
132. Haeck IM, ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen 
CA, Knol MJ. Moderate correlation between quality of life and disease activity in adult 
patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2012;26:236-41.  
133. Chernyshov PV, Ho RC, Monti F et al. An international multi-center study on 
self-assessed and family quality of life in children with atopic dermatitis. Acta 
Dermatovenerol Croat 2015;23:247-53. 
134. Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term 
parental education program on childhood atopic dermatitis: a randomized controlled trial. 
Pediatr Dermatol 2013;30:438-43.  
135. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: 
the impact of an educational intervention. Pediatr Dermatol 2006;23:428-36. 
136. Son HK, Lim J. The effect of a web-based education programme (WBEP) on 
disease severity, quality of life and mothers' self-efficacy in children with atopic 
dermatitis. J Adv Nurs 2014;70:2326-38.  
137. Staab D, Diepgen TL, Fartasch M et al. Age related, structured educational 
programmes for the management of atopic dermatitis in children and adolescents: 
multicentre, randomised controlled trial. BMJ 2006;332:933-8. 
138. Pena-Robichaux V, Kvedar JC, Watson AJ. Text messages as a reminder aid and 
educational tool in adults and adolescents with atopic dermatitis: a pilot study. Dermatol 
Res Pract 2010;2010. pii: 894258.  
139. van Os-Medendorp H, van Leent-de Wit I, de Bruin-Weller M, Knulst A. Usage 
and users of online self-management programs for adult patients with atopic dermatitis 
and food allergy: an explorative study. JMIR Res Protoc 2015;4:e57.  
140. Baron SE, Morris PK, Dye L, Fielding D, Goulden V. The effect of dermatology 
consultations in secondary care on treatment outcome and quality of life in new adult 
patients with atopic dermatitis. Br J Dermatol 2006;154:942-9. 
141. Kiebert G, Sorensen SV, Revicki D et al. Atopic dermatitis is associated with a 
decrement in health-related quality of life. Int J Dermatol 2002;41:151-8. 
142. Tejada Cdos S, Mendoza-Sassi RA, Almeida HL Jr, Figueiredo PN, Tejada VF. 
Impact on the quality of life of dermatological patients in southern Brazil. An Bras 
Dermatol 2011;86:1113-21. 
143. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-
related quality of life in patients with psoriasis and atopic dermatitis measured with SF-
36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 
2000;80:430-4. 
144. Schmitt J, Heese E, Wozel G, Meurer M. Effectiveness of inpatient treatment on 
quality of life and clinical disease severity in atopic dermatitis and psoriasis vulgaris - a 
prospective study. Dermatology 2007;214:68-76. 
145. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality 
of life, health-state utilities and willingness to pay in patients with psoriasis and atopic 
eczema. Br J Dermatol. 1999;141:1067-75. 
146. Noh S, Kim M, Park CO, Hann SK, Oh SH. Comparison of the psychological 
impacts of asymptomatic and symptomatic cutaneous diseases: vitiligo and atopic 
dermatitis. Ann Dermatol 2013;25:454-61.  
147. van Os-Medendorp H, Appelman-Noordermeer S, Bruijnzeel-Koomen C, de 
Bruin-Weller M. Sick Leave and Factors Influencing Sick Leave in Adult Patients with 
Atopic Dermatitis: A Cross-Sectional Study. J Clin Med 2015;4:535-47. 
148. Yano C, Saeki H, Ishiji T et al. Impact of disease severity on work productivity 
and activity impairment in Japanese patients with atopic dermatitis. J Dermatol 
2013;40:736-9. 
149. Hon KL, Tsang YC, Poon TC et al. Dairy and nondairy beverage consumption for 
childhood atopic eczema: what health advice to give? Clin Exp Dermatol 2016;41:129-
37.  
150. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C. Atopic 
dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence 
and comorbidities. Allergy 2015;70:836-45. 
151. Steinke S, Langenbruch A, Ständer S, Franzke N, Augustin M. Therapeutic 
benefits in atopic dermatitis care from the patients' perspective: results of the German 
national health care study 'Atopic Health'. Dermatology 2014;228:350-9. 
152. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, 
Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol 
2009;26:14-22. 
153. Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. 
Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol 
Res 2014;306:279-86. 
154. Mizawa M, Yamaguchi M, Ueda C, Makino T, Shimizu T. Stress evaluation in 
adult patients with atopic dermatitis using salivary cortisol. Biomed Res Int 
2013;2013:138027. 
155. Matterne U, Apfelbacher C. Is the impact of atopic disease on children and 
adolescents' health related quality of life modified by mental health? Results from a 
population-based cross-sectional study. Health Qual Life Outcomes 2013;11:115. 
156. Dieris-Hirche J, Milch WE, Kupfer J, Leweke F, Gieler U. Atopic dermatitis, 
attachment and partnership: a psychodermatological case-control study of adult patients. 
Acta Derm Venereol 2012;92:462-6. 
157. Chernyshov PV, Jiráková A, Hercogová J. Comparative study of the quality of life 
of children with atopic dermatitis from Ukraine and the Czech Republic. J Eur Acad 
Dermatol Venereol 2011;25:1483-4. 
158. Chernyshov PV. Gender differences in health-related and family quality of life in 
young children with atopic dermatitis. Int J Dermatol 2012;51:290-4. 
159. Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal 
scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor 
and substance P. Br J Dermatol 2007;157:922-5. 
160. Hon KL, Wang SS, Hung EC et al. Serum levels of heavy metals in childhood 
eczema and skin diseases: friends or foes. Pediatr Allergy Immunol 2010;21:831-6.  
161. Camfferman D, Kennedy JD, Gold M, Martin AJ, Winwood P, Lushington K. 
Eczema, sleep, and behavior in children. J Clin Sleep Med 2010;6:581-8. 
162. Ho RC, Giam YC, Ng TP et al. The influence of childhood atopic dermatitis on 
health of mothers, and its impact on Asian families. Pediatr Allergy Immunol 
2010;21:501-7. 
163. Potocka A, Turczyn-Jabłońska K, Kieć-Swierczyńska M. Self-image and quality 
of life of dermatology patients. Int J Occup Med Environ Health 2008;21:309-17. 
164. Ludwig MW, Oliveira Mda S, Muller MC, Moraes JF. Quality of life and site of 
the lesion in dermatological patients. An Bras Dermatol 2009;84:143-50.  
165. Manzoni AP, Weber MB, Nagatomi AR, Pereira RL, Townsend RZ, Cestari TF. 
Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin 
disorders. An Bras Dermatol 2013;88:894-9.  
166. Hon KL, Ching GK, Ng PC, Leung TF. Exploring CCL18, eczema severity and 
atopy. Pediatr Allergy Immunol 2011;22:704-7. 
167. Wittkowski A, Richards HL, Griffiths CE, Main CJ. The impact of psychological 
and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom 
Res 2004;57:195-200. 
168. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in 
patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol 
2003;111:598-602 
169. Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z et al. The unfavorable 
effects of concomitant asthma and sleeplessness due to the atopic eczema/dermatitis 
syndrome (AEDS) on quality of life in subjects allergic to house-dust mites. Allergy 
2002;57:919-25 
170. Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single 
dermatology nurse consultation in primary care on the quality of life of children with 
atopic eczema. Br J Dermatol 2002;146:432-9. 
171. Byremo G, Rød G, Carlsen KH. Effect of climatic change in children with atopic 
eczema. Allergy 2006;61:1403-10. 
172. Schut C, Mahmutovic V, Gieler U, Kupfer J. Patient education programs for 
childhood atopic dermatitis: who is interested? J Dtsch Dermatol Ges 2012;10:657-61. 
173. Langenbruch A, Radtke M, Franzke N, Ring J, Foelster-Holst R, Augustin M. 
Quality of health care of atopic eczema in Germany: results of the national health care 
study AtopicHealth. J Eur Acad Dermatol Venereol 2014;28:719-26. 
174. Schuttelaar ML, Vermeulen KM, Drukker N, Coenraads PJ. A randomized 
controlled trial in children with eczema: nurse practitioner vs. dermatologist. Br J 
Dermatol 2010;162:162-70. 
175. Jemec GB, Esmann S, Holm EA, Tycho A, Jørgensen TM. Time spent on 
treatment (TSOT). An independent assessment of disease severity in atopic dermatitis. 
Acta Dermatovenerol Alp Pannonica Adriat 2006;15:119-24. 
176. Twiss J, McKenna SP. Comparing the impact of psoriasis and atopic dermatitis on 
quality of life: co-calibration of the PSORIQoL and QoLIAD. Qual Life Res 
2015;24:105-13.  
177. Augustin M, Amon U, Bullinger M, Gieler U. Recommendations for the 
assessment of quality of life in dermatology. Dermatol Psychosom 2000;1:84-7. 
178. Holm EA, Wulf HC, Stegmann H, Jemec GB. Life quality assessment among 
patients with atopic eczema. Br J Dermatol 2006;154:719-25. 
179. van Geel MJ, Maatkamp M, Oostveen AM et al. Comparison of the Dermatology 
Life Quality Index and the Children's Dermatology Life Quality Index in assessment of 
quality of life in patients with psoriasis aged 16-17 years. Br J Dermatol 2016;174:152-7. 
180. Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug 
Targets 2009;8:398-404. 
181. Chernyshov P, de Korte J, Tomas-Aragones L, Lewis-Jones S. EADV Taskforce’s 
recommendations on measurement of health-related quality of life in paediatric 
dermatology. J Eur Acad Dermatol Venereol 2015;29:2306-16. 
182. Chernyshov P. Dermatological quality of life instruments in children. G Ital 
Dermatol Venereol 2013;148:277-85. 
183. Chernyshov PV. May the gender of a parent influence assessment of health-
related quality of life, family impact and severity of atopic dermatitis in children. Pediatr 
Dermatol 2009;26:99-100.  
184. Finlay AY, Basra MK. DLQI and CDLQI scores should not be combined. Br J 
Dermatol 2012;167:453-4. 
185. Prinsen C, de Korte J, Augustin M et al. Measurement of health-related quality of 
life in dermatological research and practice: outcome of the EADV Taskforce on Quality 
of Life. J European Acad Dermatol Venereol 2013;27:1195-203. 
 
